Skip to content
Black Friday — 30% OFFFree shipping on orders of A$99 or more
  1. Home
  2. Longevity & Cellular Health
  3. Pramipexole (Prami), 12 mg (0.2 mg/60 capsules)
Longevity

Pramipexole (Prami), 12 mg (0.2 mg/60 capsules)

Pramipexole is a non-ergoline dopamine receptor agonist with preferential affinity for D3 receptors and additional activity at D2 receptor subtypes within the D2-like receptor family.

Presentation: Pramipexole (Prami), 12 mg (0.2 mg/60 capsules).

Illustrative packaging generated with AI.

Original price was: A$40.99.Current price is: A$28.69.

Currently unavailable in Australia

Ask an advisor
An advisor contacts you and the partner pharmacy checks whether and how it can proceed. A valid prescription, or an assessment through an authorised telemedicine service, may be required.
  • Partner pharmacy
  • Personal assistance
  • Discreet delivery
  • Presentation
    Pramipexole (Prami), 12 mg (0.2 mg/60 capsules)

Shipping & Delivery

  • Normally dispatched within 24 hours of payment confirmation.
  • USPS Regular Shipping · A$11.95 · Approx. 3–5 business days
  • FedEx 2 Days Delivery · A$28.99 · Approx. 2 business days
  • FedEx Overnight Delivery · A$40.99 · Approx. 1 business day

For laboratory research only.

Not for human or veterinary use.

Composition and product details

Overview

Pramipexole is a non-ergoline dopamine receptor agonist with preferential affinity for D3 receptors and additional activity at D2 receptor subtypes within the D2-like receptor family.

Experimental investigations have examined its interactions with dopamine receptor-mediated signaling pathways, G protein-coupled receptor activation mechanisms, intracellular cAMP regulation, and receptor-ligand dynamics.

Its receptor selectivity profile makes it a valuable research tool for studies of D2/D3 receptor pharmacology, dopaminergic signaling networks, receptor subtype selectivity, signal transduction mechanisms, and comparative investigations of dopamine receptor-mediated regulatory pathways.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only

Properties

Chemical Formula C10H17N3S
Synonyms Mirapex (trade name), Sifrol (trade name), PPX, (S)-Pramipexole
Molar Mass 211.33 g/mol
CAS Number 104632-26-0
PubChem CID 119570
Total Compound Content 12 mg (0.2 mg per capsule)
Shelf Life 36 months

Research

Pramipexole ((S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine) is a non-ergoline dopamine receptor agonist with preferential affinity for D3 receptors and additional activity at D2 receptor subtypes within the D2-like receptor family. Experimental investigations have examined its interactions with dopamine receptor-mediated signaling pathways, G protein-coupled receptor activation mechanisms, intracellular cAMP regulation, and receptor-ligand dynamics. Its high D3 receptor selectivity makes it a valuable research tool for studies of D2/D3 receptor pharmacology, receptor subtype differentiation, dopaminergic signaling networks, signal transduction mechanisms, and comparative investigations of dopamine receptor-mediated regulatory pathways. Supplied in 0.2 mg capsules. Independently third-party HPLC-tested; COA available per batch.

FAQ

What is pramipexole’s receptor selectivity profile and why is D3 selectivity research-relevant?

Pramipexole exhibits preferential affinity for D3 receptors within the D2-like dopamine receptor family, with additional activity at D2 and D4 receptor subtypes. This receptor selectivity profile makes it a valuable research tool for investigating D3 receptor pharmacology, receptor subtype differentiation, dopaminergic signaling mechanisms, and comparative studies of D2-like receptor function.

Experimental investigations frequently utilize pramipexole to examine receptor-ligand interactions, signal transduction pathways, and subtype-specific dopamine receptor regulation.

How is pramipexole used in dopaminergic signaling research?

Pramipexole is widely used as a selective dopaminergic probe for studies of D2-like receptor activation, G protein-coupled receptor signaling, intracellular cAMP regulation, and dopamine receptor-mediated communication networks. Its well-characterized receptor profile allows researchers to investigate the molecular and signaling consequences of D3-preferring receptor activation and compare these effects with broader dopaminergic signaling mechanisms.

What makes pramipexole useful for dopamine receptor pharmacology studies?

Pramipexole’s high affinity for D3 receptors and established activity at D2-like receptor subtypes make it a valuable reference compound for investigations of receptor selectivity, dopamine receptor signaling pathways, ligand-receptor dynamics, and GPCR-mediated regulatory mechanisms. These characteristics support its use in mechanistic studies of dopaminergic pharmacology and comparative analyses of D2-family receptor function.

Capsule excipients are not specified in the available product documentation.